CA 72-4

CA 72-4 Full Name

Cancer Antigen 72-4

CA 72-4 Introduction

Cancer Antigen 72-4 (CA72-4), also known as Tumor-Associated Glycoprotein 72 (TAG-72), is a high-molecular-weight mucin-like glycoprotein that has become an important biomarker and therapeutic target in oncology. Researchers and clinicians frequently encounter challenges when distinguishing malignant glandular tumors from benign gastrointestinal disorders because many conventional tumor markers lack sufficient specificity. CA72-4 addresses part of this gap by recognizing cancer-associated glycan epitopes that are largely absent from normal adult tissues but enriched in embryonic tissues and a broad range of epithelial malignancies. The antigen is identified by the monoclonal antibodies B72.3 and CC49, which recognize distinct sialylated carbohydrate epitopes, including sialyl-Tn (STn) and sialyl-T antigens, on heavily O-glycosylated mucins. Rather than representing a single protein, TAG-72 consists of tumor-specific glycan clusters displayed on multiple mucin family members, including MUC1, MUC2, MUC5AC, MUC6, MUC13, and MUC17. This unique biology makes CA72-4 highly relevant for biomarker development, companion diagnostics, antibody engineering, and targeted drug delivery, particularly because its expression is minimal in most healthy adult tissues while remaining abundant in many adenocarcinomas and mucinous tumors.

The biological significance of CA72-4 extends far beyond its role as a circulating serum marker. Aberrant glycosylation is now recognized as a hallmark of malignant transformation, and TAG-72 represents one of the best-characterized examples of this process. Cancer-associated glycan remodeling alters the physical and immunological properties of mucins, enabling tumor cells to evade immune surveillance by interacting with lectin receptors such as Siglecs and macrophage galactose-type lectin (MGL), thereby suppressing antitumor immune responses. Recent mechanistic studies further suggest that complete removal of TAG-72-positive tumor tissue may help reverse immune escape and partially restore immune recognition, providing a potential explanation for improved survival observed in selected colorectal cancer patients after extensive surgical resection. Structural investigations have also demonstrated that antibody recognition of TAG-72 depends on the three-dimensional clustering of Tn and STn glycans within mucin tandem-repeat domains rather than on isolated carbohydrate residues, highlighting the conformational complexity of this antigen. In parallel, advances in glycobiology indicate that mucin architecture is dynamically influenced by O-linked glycosylation patterns and local ionic conditions, which together regulate mucin conformation and may further shape tumor microenvironment behavior and antigen accessibility.

Clinically, CA72-4 is most strongly associated with gastric cancer, where elevated serum concentrations correlate with advanced disease stage, postoperative recurrence, and less favorable prognosis. However, its clinical relevance extends well beyond gastric malignancies, with substantial expression reported in ovarian cancer, colorectal cancer, pancreatic cancer, breast cancer, and other mucin-producing adenocarcinomas. Although CA72-4 is not recommended as a standalone screening marker because of limited sensitivity in early-stage disease, it provides significant value when combined with established biomarkers such as CEA and CA19-9 for diagnosis, treatment monitoring, and recurrence surveillance. Growing evidence also supports its utility as a predictive biomarker for patient stratification in precision oncology. The highly restricted distribution of TAG-72 in normal tissues has accelerated the development of targeted therapeutics, including next-generation antibody-drug conjugates (ADCs) that exploit tumor-selective glycan epitopes for improved efficacy while minimizing off-target toxicity. Novel TAG-72-directed ADC platforms, together with standardized immunohistochemical assays using B72.3 and CC49 clones, are expanding opportunities for companion diagnostics and personalized cancer therapy, reinforcing CA72-4 as both a clinically valuable biomarker and an increasingly attractive pan-tumor therapeutic target.

Alternate Names for CA 72-4

CA 72-4; Cancer Antigen 72-4; CA 72 4; CA72-4

• Tumor Marker Catalogue
• Tumor Marker Catalogue

• 1.Hitchcock CL, et al.; Survival Advantage Following TAG-72 Antigen-Directed Cancer Surgery in Patients With Colorectal Carcinoma: Proposed Mechanisms of Action. Front Oncol. 2021, 11:731350.
  2.Xu Y, et al.; The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer. Biochim Biophys Acta Rev Cancer. 2021, 1876(2):188634.